METAVIA INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
METAVIA INC. (MTVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 2.14 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-03-26
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-12-31 was -21.43K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-09-30 was 0.00 shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2025 was 2.14K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 7.03K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | -21.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -21.43K shares derived: sum of 2 quarters · filed 2026-03-26 | 2.14K shares 10-K · filed 2026-03-26 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 23.57K shares 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 23.57K shares 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | 7.03K shares 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |